Compare ETW & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Current Price
| Metric | ETW | VALN |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.1M | 820.0M |
| IPO Year | N/A | 2021 |
| Metric | ETW | VALN |
|---|---|---|
| Price | $9.26 | $9.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.75 |
| AVG Volume (30 Days) | ★ 284.6K | 24.9K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $211,089,992.00 |
| Revenue This Year | N/A | $3.64 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.48 |
| 52 Week Low | $6.96 | $4.20 |
| 52 Week High | $8.49 | $12.25 |
| Indicator | ETW | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 54.82 | 63.27 |
| Support Level | $9.16 | $8.77 |
| Resistance Level | $9.34 | $10.03 |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | -0.00 | 0.18 |
| Stochastic Oscillator | 60.00 | 86.07 |
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.